Vertex Pharmaceuticals Incorporated VRTX34.SA Stock
Vertex Pharmaceuticals Incorporated Price Chart
Vertex Pharmaceuticals Incorporated VRTX34.SA Financial and Trading Overview
Vertex Pharmaceuticals Incorporated stock price | 504.39 BRL |
Previous Close | 413.13 BRL |
Open | 0 BRL |
Bid | 417.79 BRL x N/A |
Ask | 0 BRL x N/A |
Day's Range | 0 - 0 BRL |
52 Week Range | 0 - 439.32 BRL |
Volume | 0 BRL |
Avg. Volume | 78 BRL |
Market Cap | 432.38B BRL |
Beta (5Y Monthly) | 0.494014 |
PE Ratio (TTM) | 27.2095 |
EPS (TTM) | 17.7 BRL |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
VRTX34.SA Valuation Measures
Enterprise Value | 415.98B BRL |
Trailing P/E | 27.2095 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 46.957333 |
Price/Book (mrq) | 29.847624 |
Enterprise Value/Revenue | 45.176 |
Enterprise Value/EBITDA | 90.071 |
Trading Information
Vertex Pharmaceuticals Incorporated Stock Price History
Beta (5Y Monthly) | 0.494014 |
52-Week Change | 21.72% |
S&P500 52-Week Change | 20.43% |
52 Week High | 439.32 BRL |
52 Week Low | 0 BRL |
50-Day Moving Average | 416.57 BRL |
200-Day Moving Average | 397.79 BRL |
VRTX34.SA Share Statistics
Avg. Volume (3 month) | 78 BRL |
Avg. Daily Volume (10-Days) | 56 BRL |
Shares Outstanding | 1.03B |
Float | 1.03B |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.0010% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 35.40% |
Operating Margin (ttm) | 48.51% |
Gross Margin | 59.05% |
EBITDA Margin | 50.15% |
Management Effectiveness
Return on Assets (ttm) | 16.80% |
Return on Equity (ttm) | 25.72% |
Income Statement
Revenue (ttm) | 9.21B BRL |
Revenue Per Share (ttm) | 8.97 BRL |
Quarterly Revenue Growth (yoy) | 13.20% |
Gross Profit (ttm) | 5.32B BRL |
EBITDA | 4.62B BRL |
Net Income Avi to Common (ttm) | 3.26B BRL |
Diluted EPS (ttm) | 15.37 |
Quarterly Earnings Growth (yoy) | -8.20% |
Balance Sheet
Total Cash (mrq) | 10.41B BRL |
Total Cash Per Share (mrq) | 10.11 BRL |
Total Debt (mrq) | 789.2M BRL |
Total Debt/Equity (mrq) | 5.47 BRL |
Current Ratio (mrq) | 4.284 |
Book Value Per Share (mrq) | 14.0115 |
Cash Flow Statement
Operating Cash Flow (ttm) | 4.07B BRL |
Levered Free Cash Flow (ttm) | 3.63B BRL |
Profile of Vertex Pharmaceuticals Incorporated
Country | Brazil |
State | MA |
City | Boston |
Address | 50 Northern Avenue |
ZIP | 02210 |
Phone | 617 341 6100 |
Website | https://www.vrtx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 4800 |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Q&A For Vertex Pharmaceuticals Incorporated Stock
What is a current VRTX34.SA stock price?
Vertex Pharmaceuticals Incorporated VRTX34.SA stock price today per share is 504.39 BRL.
How to purchase Vertex Pharmaceuticals Incorporated stock?
You can buy VRTX34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vertex Pharmaceuticals Incorporated?
The stock symbol or ticker of Vertex Pharmaceuticals Incorporated is VRTX34.SA.
Which industry does the Vertex Pharmaceuticals Incorporated company belong to?
The Vertex Pharmaceuticals Incorporated industry is Biotechnology.
How many shares does Vertex Pharmaceuticals Incorporated have in circulation?
The max supply of Vertex Pharmaceuticals Incorporated shares is 1.03B.
What is Vertex Pharmaceuticals Incorporated Price to Earnings Ratio (PE Ratio)?
Vertex Pharmaceuticals Incorporated PE Ratio is 28.49661000 now.
What was Vertex Pharmaceuticals Incorporated earnings per share over the trailing 12 months (TTM)?
Vertex Pharmaceuticals Incorporated EPS is 17.7 BRL over the trailing 12 months.
Which sector does the Vertex Pharmaceuticals Incorporated company belong to?
The Vertex Pharmaceuticals Incorporated sector is Healthcare.